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Outcome of HIV infected patients on continuous ambulatory peritoneal
dialysis. A retrospective analysis of 39 HIV infected patients with
ESRD cared for in New Haven from 1987 to June 1992 was performed.
All patients had evidence for HIV infection at the start of CAPD
therapy. Cumulative technique survival at one and two years was 43%
and 27%, respectively. Only eight patients transferred to center dialy-
sis. One and two year patient survival on CAPD was 58% and 54%,
respectively. Mortality was higher in patients with advanced infection
than in those with asymptomatic HIV infection. Hospitalization rates
were also higher in patients with advanced infection. HIV infected
patients had higher rates of peritonitis (3.9 episodes/outpatient CAPD
year) compared to non-HIV infected patients (1.5 episodes/CAPD
year), especially for pseudomonal and fungal infections. Active injec-
tion drug use and use of the "straight set" system were associated with
increased rates of peritonitis. CAPD deserves consideration as a
therapy for HIV infected patients with ESRD.
The Acquired Immunodeficiency Syndrome (AIDS) epidemic
continues to expand with about 250,000 cases reported in the
United States to date. There are an estimated 40,000 to 50,000
new infections with Human Immunodeficiency Virus (HIV)
annually in the United States [1]. Renal complications have
been reported in 6 to 10% [2—41 of hospitalized patients infected
with HIV, and as many as half may result in the development of
end-stage renal disease (ESRD) [5]. Institution of chronic
dialysis therapy for HIV infected individuals who develop
end-stage renal disease is becoming generally accepted [4, 6].
Selecting the best modality of renal replacement therapy
presents a clinical and psychosocial challenge [7]. Unfortu-
nately, there is little information in the literature to guide the
nephrologist on this issue. Experiences with HIV infected
patients on maintenance hemodialysis have been reported,
including data concerning hospitalizations [8], mortality, and
progression of the underlying HIV infection [4]. However, no
large scale experience has examined similar outcomes in HIV
infected patients maintained on continuous ambulatory perito-
neal dialysis (CAPD). Despite this, CAPD is the treatment
selected by many centers [9] for patients with HIV infection
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who develop ESRD. Complications related to peritoneal dialy-
sis in this patient population may pose special problems. For
example, the incidence and spectrum of peritonitis in small
series of HIV infected patients on CAPD [10—12] have been
reported to differ from the general population of CAPD pa-
tients.
In the present study, we report our experience with 39 HIV
infected patients with ESRD treated with maintenance CAPD
between January 1987 and June 1992. Attention is focused on
patient and technique survival, noting the relationship of these
factors to stage of HIV infection and CD4+ T-lymphocyte
counts, peritonitis and catheter exit-site infection rates, and
causes and rates of hospitalizations.
Methods
All HIV seropositive patients cared for by the CAPD unit in
New Haven, Connecticut between January 1987 and June 30,
1992 were included in the present study. All patients were
adults who: (1) had positive HIV antibody by enzyme immu-
noassay (ELISA), confirmed by Western blot and (2) had
completed four weeks (28 days) of maintenance CAPD therapy.
Thirty-nine patients met the above criteria. Three HIV+ pa-
tients with ESRD who started CAPD were excluded from the
study because they did not complete 28 days of maintenance
CAPD. Of HIV infected patients with ESRD in New Haven
who initiated chronic dialysis between January 1987 and June
30, 1992 42 (84%) began CAPD and eight (16%) began chronic
hemodialysis.
Maintenance CAPD was defined as starting the day the
patient began outpatient training and ended with the earlier of:
(1) death; (2) dropout from CAPD; (3) geographic relocation; or
(4) June 30, 1992. Dropout was defined as a permanent transfer
to another dialysis modality or recovery of renal function.
Temporary transfers to hemodialysis of less than 45 days
duration with return to CAPD therapy were considered as
continued maintenance CAPD therapy.
All CAPD training took place in an outpatient setting as
previously described [13]. Patients were trained in a nonran-
domized fashion to a Y-disconnect (Baxter) or a straight system
according to nurse preference.
A renal biopsy was not a requirement for entry. Sixteen
patients had renal biopsies which were reviewed by a single
pathologist blinded to the HIV status of the patient. Each
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Table 1. HIV infected patients on CAPD
Black;a Age at the initiation of maintenance CAPD; abbreviations are: B, W,b Behavior which put patient at risk for HIV infection, as defined in Methods
' Active drug use while on maintenance CAPD
d Episodes of peritonitis while on maintenance CAPD
Technique survival in days from initiation of maintenance CAPD
Patient survival in days from initiation of maintenance CAPD
g Days spent in the hospital while on maintenance CAPD
biopsy was read as consistent with or not consistent with HIV
nephropathy as characterized by glomerular, tubular and inter-
stitial abnormalities [14].
The inpatient and outpatient records of cases were retrospec-
tively reviewed for specific clinical and demographic data.
Thirty-eight patients had positive HIV serologies available
within two months of the initiation of CAPD. The 39th patient
(#35) had a renal biopsy prior to the initiation of CAPD which
was consistent with HIV nephropathy and a positive serology
for HIV documented 29 months after the initiation of CAPD.
Absolute CD4 positive T-lymphocyte counts which were ob-
tained closest to the initiation of CAPD were considered to be
the CD4 count at the initiation of CAPD. The mean time (± SD)
between the initiation of CAPD and the date CD4 counts were
obtained was 5 4.4 months.
Risk behaviors for HIV infection were listed hierarchically as
previously described [41 for patient classification in the follow-
ing order: (1) injection drug users (IDU); (2) men who had sex
with other men (MSM); (3) patients who had heterosexual
contact with known HIV infected partners; (4) patients who
received contaminated blood products; and (5) patients in
whom no risk factor was identified.
The patients were put into two groups for staging of HIV
infection for analysis. The most advanced stage of HIV disease
identified for each patient during the period of observation was
the stage used for all analyses. Asymptomatic infection, which
included patients from CDC class II and III [15], describes
patients with serologic evidence of HIV infection, but no
symptoms of illness with the exception of lymphadenopathy
and CD4 counts 200 cells/cubic mm. Advanced infection,
which included patients from CDC class IV [15], describes
patients with constitutional, neurologic, infectious or other
Pt Age Race/sexa Risk"
Active
IVDAC Set Perd
Reason
left CAPD
Tech
surv
Pt
surv
Hosp
days5
Final
Outcome
1 36 BF IDU no y-set 0 died 28 30 8 dead
2 35 BM IDU unk y-set 0 died 72 72 22 dead
3 31 BF IDU unk y-set 1 peritonitis 59 85 43 dead
4 37 BM IDU unk y-set 0 recovery 55 110 13 alive
5 38 BM IDU yes y-set 0 died 111 114 47 dead
6 35 BM IDU unk straight 2 peritonitis 86 117 25 dead
7 31 BM IDU yes y-set 0 died 120 120 31 dead
8 27 BF unk no y-set 1 died 169 169 48 dead
9 29 BM IDU unk y-set 2 peritonitis 83 178 51 dead
10 35 BM IDU yes y-set 2 died 204 209 50 dead
11 33 BF unk no y-set 0 died 224 224 37 dead
12 44 BM MSM no straight 5 debilitated 247 289 37 dead
13 31 WM MSM no y-set 1 — 301 301 205 alive
14 43 BM IDU no y-set 3 died 387 387 59 dead
15 41 BM IDU unk straight 1 compliance 174 409 121 dead
16 50 BM unk no straight 5 moved 489 763 117 alive
17 43 BM unk no y-set 6 died 801 801 80 dead
18 28 BF IDU unk y-set 0 — 43 43 0 alive
19 48 BF heter no y-set 2 died 45 45 0 dead
20 27 BM IDU unk straight 2 died 49 49 30 dead
21 44 BM IDU unk y-set 0 — 113 113 0 alive
22 49 BM IDU no y-set 0 — 120 120 0 alive
23 41 BM IDU yes y-set 1 died 127 131 7 dead
24 30 WM MSM no y-set 0 — 134 134 0 alive
25 43 BM IDU unk y-set 2 died 147 147 67 dead
26 36 BF unk no y-set 0 — 148 148 0 alive
27 50 BF heter no y-set 5 died 168 168 81 dead
28 40 BM IDU yes straight 5 died 215 215 29 dead
29 43 BM IDU yes straight 10 peritonitis 256 307 36 dead
30 44 BM IDU yes straight 9 peritonitis 365 428 69 dead
31 36 BM IDU yes y-set 12 — 448 448 48 alive
32 37 WM IDU no y-set 2 — 507 507 49 alive
33 45 BM IDU yes y-set 1 — 582 582 1 alive
34 32 OM unk no y-set 1 — 589 589 7 alive
35 37 BM IDU unk y-set 1 died 899 899 33 died
36 33 BM IDU yes straight 12 peritonitis 708 1056 145 alive
37 26 HF IDU yes y-set 8 — 1166 1166 141 alive
38 39 BM IDU unk straight 11 died 1268 1268 53 died
39 40 BM IDU no straight 9 — 1562 1562 152 alive
Caucasian; 0, Oriental; H, Hispanic; F, female; M, male
Table 1. Continued
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Pt CD4"
HIV
stag&
AIDS index
diagnosi&
AIDS before
CAPDk AZT' PCP Prophtm
1 114 Advanced PCP + 17.0 no no
2 0 Advanced esoph C. +2.3 yes yes
3 20 Advanced PCP +1.6 yes yes
4 31 Advanced PCP +1.4 yes yes
5 1 Advanced x-pulm TB + 55.6 yes yes
6 Advanced esoph C. —2.2 no no
7 0 Advanced esophC. +4.5 yes no
8 4 Advanced PCP + 12.0 yes no
9 40 Advanced esophC. —1.6 yes yes
10 130 Advanced PCP +22.5 yes yes
11 0 Advanced PCP +32.1 yes yes
12 2 Advanced dissem MAC —7.4 yes yes
13 40 Advanced x-pulm cryp —8.9 yes yes
14 12 Advanced esophC. —2.3 yes no
15 7 Advanced PCP +0.3 yes no
16 220 Advanced x-pulm cryp —13.1 yes yes
17 3 Advanced x-pulm cryp —5.5 yes yes
18 950 Asympt no no
19 Advanced yes no
20 76 Advanced yes no
21 21 Advanced no no
22 Asympt yes no
23 134 Advanced yes yes
24 1540 Asympt no no
25 47 Advanced yes no
26 470 Asympt no no
27 Advanced no no
28 330 Asympt no no
29 1280 Asympt no no
30 Asympt no no
31 430 Asympt yes no
32 310 Advanced yes no
33 660 Asympt no no
34 378 Asympt yes no
35 Advanced no no
36 670 Asympt no no
37 271 Advanced yes yes
38 Asympt no no
39 193 Advanced no no
h CD4 T-lymphocyte count/mm3 at initiation of maintenance CAPD
Most advanced stage identified for the patient as of June 30, 1992
Abbreviations are: PCP, pneumocystis carinii pneumonia; esoph C., esophageal candidiasis; x-pulm TB, extrapulmonary Mycobacterium
tuberculosis; dissem MAC, disseminated Mycobacterium avium complex; x-pulm cryp, extrapulmonary Cryptococdus infection
k Numberof months AIDS diagnosis preceded initiation of CAPD: (+) = AIDS diagnosis was made before initiation of maintenance CAPD, (—)
= AIDS diagnosis was made after initiation of maintenance CAPD
Patient was prescribed zidovudine
m Patient was prescribed a standard PCP prophylaxis regimen
complications of HIV infection, as well as asymptomatic pa-
tients with CD4 counts less than 200 cells/cubic mm (consistent
with 1992 CDC revised AIDS case definition [16]). This group
also included patients who met the 1987 AIDS case definition
[17].
Peritonitis was defined by the presence of any two of the
following: (1) positive peritoneal fluid culture; (2) abdominal
pain; and (3) peritoneal leukocyte count greater than 100 per
cubic mm. Only peritonitis episodes which occurred while on
maintenance dialysis in the outpatient setting were included in
this analysis. Therefore, hospital acquired infections and epi-
sodes of peritonitis that occurred prior to the initiation of
outpatient CAPD training were excluded.
Catheter exit-site infections were defined as previously de-
scribed [181 by the presence of pericatheter erythema, tender-
ness and drainage (purulent or nonpurulent). Exit site infections
were attributed to the organism(s) identified by culture if the
above findings were present in association with a positive
exit-site culture.
Life tables were constructed according to the Kaplan Meier
method. Technique survival was defined as the percentage of
patients remaining on CAPD at defined time intervals after the
initiation of maintenance CAPD. Patient survival on CAPD was
defined as the percentage of patients remaining alive on CAPD
at defined time intervals after the initiation of maintenance
CAPD, considering as death only patient deaths occurring while
on CAPD or within five days of stopping CAPD. Patients
recovering renal function and patients transferred to other
dialysis centers were considered as lost to follow-up. Overall
patient survival was defined as the percentage of patients
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Table 2. Demographic features of HIV infected and all CAPD
patients
HIV infected
pts(N=39)
All CAPD
pts(N=474) P
Mean age (range) 37.6 years (26—50) 52.3 years
Gender =0.016
Female 23% 42.8%
Male 77% 57.2%
Race <0.0001
Black 87% 32.7%
White 7.7% 63.3%
Hispanic 2.6% 3.0%
Other 2.6% 1.0%
HIV riska
IDU 72%
MSM 7.7%
Heter 7.7%
Unk 13%
Fig. 1. Overall survival of HI V-infected patients on CAPD: Asymp-
tomatic vs. advanced HIV infection. Kaplan-Meier estimates of prob-
ability of surviving after initiation of CAPD. Symbols are: (- - -)
asymptomatic group, N = 12, median CD4 = 660; (—) advanced
group, N = 27 (includes all with CD4 < 200, or with symptoms of HIV
disease), median CD4 = 31. Tick marks represent censored observa-
tions. Survival probability was significantly longer in the asymptomatic
group (P = 0.03, log-rank analysis).
remaining alive at defined time intervals from the initiation of
maintenance CAPD regardless of transfer to center dialysis,
relocation or recovery of renal function.
Data were processed with a database on a personal computer.
Mann Whitney U, Chi square, Mantel-Haenzel, and Fisher's
exact tests were employed as appropriate. Peritonitis rates were
calculated by dividing the total number of peritonitis episodes
by the total number of outpatient days on maintenance CAPD,
and multiplying by 365,2 days/year. Outpatient days on CAPD
were calculated by subtracting the number of days spent in the
hospital while on maintenance CAPD from the total number of
days on maintenance CAPD.
12 months 24 months 36 months
Technique survival 43% 27% 16%
Patient survival on CAPD 58% 54% 32%
No.
admissions
%Of
totala
Peritonitis 72 48%
Fluid overload 8 5%
Exit site infection or catheter related 11 7%
Other infections, not HIV related 18 12%
HIV related complications 22 15%
Other 33 22%
Results
Clinical and demographic data
Between January 1, 1987 and June 30, 1992 the CAPD unit
cared for 474 patients with ESRD, representing 7693 patient
months of therapy (Tables 1 and 2). Thirty-nine (8.2%) patients
were HIV positive and represented 435 patient months of
therapy. General demographic data are listed in Table 2.
Median length of follow-up for all HIV infected patients from
initiation of maintenance CAPD was 6.9 months (range 1 to
51.4).
Sixteen patients had renal biopsies. Thirteen had pathology
consistent with HIV nephropathy, two had chronic glomerulo-
sclerosis, and one had lupus nephritis.
Twelve patients (31%) had asymptomatic HIV infection.
Twenty-seven (69%) had advanced infection, including 17 who
met the 1987 CDC case definition for AIDS [17]. AIDS defining
opportunistic infections were: Pneumocystis carinii pneumonia
(PCP, 7 cases); esophageal candidiasis (5 cases); extra-pulmo-
nary cryptococcal infection (3 cases); disseminated Mycobac-
tenum avium complex (MAC, 1 case); and extrapulmonary
tuberculosis (1 case).
100
90
80
C 70>
60
" 50
4030
20
10
0
Time, months
Fig. 2. Kaplan Meier estimates of cumulative technique (—) and
patient (- - -) survival of HIV positive patients on CAPD. Tick marks
represent censored observations.
6 12 18 24 30 36 42 48 54 60
a Behavior which put patient at risk for HIV is defined in Methods:
IDU, injection drug users; MSM, men who had sex with other men;
Heter, patients who had heterosexual contact with known HIV infected
partners; Unk, patients with no risk factor identified
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Table 3. Hospital diagnoses for all HIV infected patients
(151 admissions; 39 patients)
6 12 18 24 30 36 42 48 54 60
Time, months
a Exceeds 100% due to multiple reasons for some hospitalizations
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Table 4. Spectrum of peritonitis
HIV in
12
3
fected patients
1 episodes
9 patients
Patients without HIV infection
903 episodes
435 patients
Number Percent Number Percent
episodes of totala episodes of total" p
Gram-positive cocci 62 51.6% 596 66% =0.002C
coag. neg. Staph 35 28.9%
S. aureus 16 13.2%
Enterococci 6 5.0%
Streptococci 9 7.4%
Other 2 1,7%
Gram-negative bacilli 30 24.4% 172 19% =NS
Pseudomonas 10 8.3% 27 3% 0.008
Acinetobacter 16 13.2%
Enterobacter 5 4.1%
Klebsiella 4 3.3%
Fungi 9 7.4% 19 2% =0.002C
Neisseria 1 0.8%
M. avium complex 1 0.8%
Culture negative 22 18.2% 181 20% =NS
Polymicrobial 12 9.9%
a Exceeds 100% due to polymicrobial infectionsb Exceeds 100% due to polymicrobial infections
C Fisher's exact test
Overall patient survival, CD4 count and stage of HIV disease
By June 30, 1992, 24 of the 39 patients had died, one patient
had recovered renal function, one patient had relocated but
remained alive, one patient remained alive on hemodialysis and
12 patients remained alive on CAPD (Fig. 1). The death rate for
all 39 HIV infected patients was 0.604 deaths/year of observa-
tion from initiation of maintenance CAPD. Survival data were
further evaluated with regard to the stage of HIV disease.
Overall patient survival curves for early and advanced HIV
infection shown in Figure 1 reflect the percentage of patients
alive from the initiation of CAPD, regardless of transfers to
other modes of dialysis, relocation or recovery of renal func-
tion.
Twelve patients with asymptomatic HIV infection were ob-
served for a median period of 12.1 months (range 1.4 to 41.7)
from the initiation of maintenance CAPD. The median CD4
count in this group was 660 cells/cubic mm (271 to 1540). Four
of these patients died (death rate = 0.27/year of observation)
with a median survival of 12.1 months (range 7.1 to 41.7).
Sudden death in the outpatient setting occurred in two (#29,
#28) who were both active drug users. Ischemic bowel was the
cause of death in a third patient (#30) and the fourth patient
(#38) died of sepsis. Eight of the patients with asymptomatic
HIV infection remained alive after a median observation period
of 9.8 months (range 1.4 to 34.7).
Twenty-seven patients with advanced HIV infection were
observed for a median period of 5.5 months (range 1.0 to 51.3)
from the initiation of maintenance CAPD. The median CD4
count in this group was 31 cells/cubic mm (range 0 to 310).
Twenty of these patients died [death rate = 0.8 deaths/year of
observation; P = 0.04 (Mantel-Haenszel) vs. asymptomatic
infection} after a median survival of 5.2 months (range 1 to 30).
The remaining seven were alive after a median observation
period of 16.7 months (range 3.6 to 51.4). Overall patient
survival was significantly longer in asymptomatic patients than
in patients with advanced disease (P = 0.03, Fig. 1).
Of the 27 patients with advanced HIV infection, 17 met the
1987 AIDS case definition [17]. Fourteen of these patients died
(death rate = 1.17 deaths/year of observation). The median
survival was 12.1 months (range 1.6 to 59.3) from the date of
AIDS diagnosis in these 14 patients.
Technique and patient survivals on CAPD
The one and two year cumulative technique survivals for all
HIV infected patients were 43% and 27%, respectively (Table 1,
Fig. 2). The one and two year patient survivals on CAPD for all
HIV infected patients were 58% and 54%, respectively. This
definition differs from overall patient survival (Fig. 1) in that
patient survival on CAPD reflects the percentage of patients
remaining alive on CAPD, considering as death only patient
deaths occurring while on CAPD or within five days of stopping
CAPD. Patients recovering renal function and patients trans-
ferred to other dialysis centers were considered as lost to
follow-up by this definition.
Twenty-seven (69%) of the HIV infected patients were no
longer on CAPD by the end of the observation period. Death on
CAPD (17 of 27) accounted for 63% these terminations. One
patient (#16) moved out of the area. Dropout from CAPD
occurred in the remaining nine patients. One patient (#4)
recovered renal function. The other eight patients transferred to
center intermittent peritoneal dialysis (IPD) or hemodialysis.
Peritonitis related complications accounted for six of eight
(75%) transfers. One patient (#12) became too debilitated to
continue his exchanges. One patient (#15) transferred to center
IPD for psychosocial reasons.
Hospitalizations
The HIV infected CAPD patients had 151 hospitalizations
covering 1942 hospital days, giving a rate of 53.4 hospital
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days/maintenance CAPD year (Tables I and 3). Eleven hospi-
talizations (7.3%) were over 30 days duration. Dialysis related
complications contributed to over 50% of admissions, including
peritonitis (47.7%) and exit site infections and catheter related
problems (7.3%). Problems related to HIV complications con-
tributed to 22 (14.6%) of the admissions.
There was a significant difference between hospitalization
rates according to stage of HIV infection. Patients with asymp-
tomatic HIV infection were hospitalized 29.1 days/year com-
pared with 67.6 days/year for patients with advanced HIV
infection (P <0.0001). Peritonitis and catheter related problems
accounted for 76% of admissions for those patients with asymp-
tomatic infection, but only 39% of admissions for those patients
with advanced infection. HIV related complications contrib-
uted to 22% of hospital admissions in patients with advanced
infection.
Peritonitis
The overall rate of peritonitis in the HIV infected patients
was 121 episodes in 372 outpatient CAPD months or 3.9
episodes/outpatient CAPD year (Tables 1 and 4). For the same
period of observation, the peritonitis rate for the 435 patients
cared for by the New Haven CAPD unit who were not known
to be HIV infected was 1.5 episodes/patient year (P <0.001). It
was of interest that the peritonitis rate was higher in patients
with asymptomatic HIV infection than in patients with ad-
vanced HIV infection (5.0 vs. 3.3 episodes/outpatient CAPD
year, P = 0.015). HIV infected active injection drug users had
a significantly higher rate of peritonitis than known non-drug
users (5.8 vs. 2.9 episodes/outpatient CAPD year, P < 0.001).
Comparison of the straight set and Y-disconnect systems
revealed that HIV infected patients trained on the straight
system had a significantly increased rate of peritonitis (7.1 vs.
2.6 episodes/outpatient CAPD year, P < 0.001). Comparison of
the peritonitis rates between the HIV+ patients on the Y-dis-
connect system (2.6 episodes/outpatient CAPD year) and
CAPD patients not known to be infected with HIV (1.5 epi-
sodes/CAPD year) revealed a significantly increased rate in the
HIV+ patients (P < 0.001). For Y-set trainees only, known
active drug users had a higher rate of peritonitis than nonusers
(3.6 vs. 2.5 episodes/outpatient CAPD year), but this difference
did not reach significance.
The most frequently identified cause of outpatient acquired
peritonitis in HIV infected patients was gram-positive cocci
(51.6%), followed by gram-negative bacilli (24.4%) and fungi
(7.4%). Pseudomonas species accounted for 8.3% of total
episodes of peritonitis in HIV infected patients. During the
same period of time in the patients on CAPD who were not
known to be HIV infected, 3% of the episodes were caused by
pseudomonas species (P = 0.008 vs. HIV infected patients) and
2% by fungi (P = 0.002 vs. HIV infected patients).
Exit site infections
There were 22 exit site infections in 14 HIV infected patients
over the period of observation (435 patient months). Of these,
16 exit sites were cultured. S. aureus was the most commonly
cultured organism (13 of 16 or 81%). Other organisms cultured
from exit site infections included P. aeruginosa (1 of 16 or
6.3%), P. mirabilis (1 of 16 or 6.3%) and S. epidermidis (1 of 16
or 6.3%). The catheter was removed in only four cases,
including the one pseudomonas and two S. aureus exit site
infections.
Discussion
Overall patient survival
The prognosis of HIV infected patients who develop end-
stage renal disease has been controversial. Early reports sug-
gested an extremely poor prognosis for AIDS patients starting
hemodialysis. Rao, Friedman and Nicastri [2] reported a me-
dian survival of 1.4 months (range 1 to 9) in this patient
population. Bourgoignie, Meneses and Pardo [3] noted that of
HIV infected patients with ESRD, most of whom had AIDS,
only 45% left the hospital to start maintenance dialysis. Subse-
quent observers, however, recognized that some AIDS patients
with ESRD survived on outpatient hemodialysis longer than
originally reported [4, 8]. Prognosis on hemodialysis has been
observed to be better for HIV infected patients without AIDS
[4, 8] than those with AIDS. Survival of HIV infected patients
on CAPD has not previously been examined.
The present study extends these observations by examining
the course of HIV infected individuals who have developed
ESRD and have been treated with outpatient CAPD therapy.
Median cumulative overall patient survival in the 39 HIV
infected patients from initiation of CAPD was 10 months.
Patients with asymptomatic infection had a significantly longer
overall survival in the present study than did patients with
advanced infection as demonstrated by life table analysis and
by differences in death rates (0.27 vs. 0.8 deaths/year of
observation, respectively). Thus, the clinical and immunologic
stage of HIV infection appears to be an important determinant
of survival in HIV infected patients on CAPD.
The impact of ESRD on patient survival in AIDS patients has
not been critically examined. Patient survival after a diagnosis
of AIDS in the non-ESRD population is variable. Factors which
have been associated with differences in survival include AIDS
index diagnosis, demographic features, mode of infection,
location of treatment, and use of anti-retroviral therapy [18—22].
In reports examining non-ESRD patients, median survival
times from AIDS diagnosis have ranged from five months in a
previous study in New Haven [231 to 13.5 months in England
[24]. Many of these studies, however, were performed prior to
widespread use of antiretroviral therapy. Friedland et a! [19]
observed a population demographically similar to the patients in
our study and noted an overall median survival of 9.5 months,
which varied from 12.8 months in patients with an index
diagnosis of Kaposi's sarcoma, to 10.9 months in patients
presenting with PCP, to less than one month for patients with
central nervous system lymphoma or disseminated cryptococ-
cal disease. Lemp eta! [25], reported a median survival of 11.1
months for women with AIDS and 14.6 months for men with
AIDS. Moore eta! [22], examined differences in survival among
patients with AIDS in Maryland. He found the median survival
after diagnosis of AIDS was 10.1 months in patients diagnosed
between 1983 and 1985, whereas it was 14.8 months in those
diagnosed after 1987, when the use of zidovudine became
widespread. The median survival of 12.1 months from the time
of AIDS diagnosis in 14 of our patients who died after meeting
the CDC case definition [171 for AIDS therefore, compares
favorably to the survival for patients without ESRD. Median
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survival from AIDS diagnosis in patients on hemodialysis has
ranged from 1 to 16 months [4, 8].
Technique and patient survivals on CAPD
Technique survival in our HIV population was 43% at one
year and 27% at two years. This is substantially lower than the
technique survivals of 68% at one year and 50% at two years
recently reported in a multicenter study of unselected CAPD
patients [261. The lower technique survival in the HIV infected
patients is largely due to the high mortality rate in these
patients, with 63% of terminations accounted for by death.
Transfers to center dialysis were infrequent. Unlike the
results in Graham's survey [9] of HIV+ patients on CAPD
where 39% of the dropouts were due to inability to continue self
care, we found only one patient out of eight (12.5%) who
transferred because of medical debilitation. The majority (75%)
of transfers were due to peritonitis related complications, as is
the case in the general population of CAPD patients [261.
Peritonitis
Fungal and pseudomonal peritonitis are of particular concern
in the CAPD population because of the high incidence of
catheter loss associated with these infections [27, 28]. Other
studies have suggested that not only is the overall rate of
peritonitis higher in HIV+ patients, but that these particular
organisms contribute to a higher percentage of peritonitis
episodes than in the general CAPD population [11, 121. Our
results substantiate a higher overall risk of peritonitis (P <
0.001) as well as a higher percentage of episodes attributed to
pseudomonas species (P = 0.008) and fungi (P = 0.002) in HIV
infected patients.
It has been suggested that the increased risk of peritonitis in
HIV infected patients on CAPD could be explained by their
behavior, rather than their HIV status. Dressier, Peters and
Lynn [11] failed to find a significant difference in peritonitis
rates between HIV+ patients on CAPD and patients on CAPD
who practiced high HIV risk behaviors but were HIV negative.
The suggestion that increased peritonitis rates in HIV infected
patients is, in part, due to behavior is supported by our finding
that the overall risk for peritonitis in active parental drug users
was significantly higher than in nonusers.
The type of CAPD system used appears to be an important
factor affecting peritonitis rates in the general CAPD population
[29]. The present study extends this observation to HIV in-
fected patients in that those patients trained on the straight
system had a significantly increased rate of peritonitis com-
pared to those trained on the Y-set.
Hospitalizations
The mean hospitalization rate of 53.4 days/maintenance
CAPD year seen in our HIV+ patients is substantially higher
than the 20 to 23 hospital days/year reported in the literature for
CAPD patients in general [30]. Similar to the general experience
[30], dialysis related complications (peritonitis and catheter
related problems) contributed to just over 50% of hospital
admissions in the HIV+ population.
There was a substantial and significant difference between
hospitalization rates according to stage of HIV infection. Pa-
tients with advanced HIV infection spent over twice the num-
ber of days in hospital than patients with asymptomatic HIV
infection. Peritonitis was the major reason for admission in the
patients with asymptomatic HIV infection.
Feinfeld et al [8] noted that five AIDS patients on mainte-
nance hemodialysis had 15 hospitalizations over 66 patient
months, four (27%) of which were longer than one month
duration. The 39 HIV infected patients in our study had 151
hospitalizations over 436 patient months on CAPD, only eleven
(7.3%) of which were over 30 days duration. There are no other
reports of hospitalization rates in HIV infected patients main-
tained on dialysis.
Conclusion
Survival of HIV infected patients with ESRD maintained on
CAPD is correlated with stage of HIV infection. Survival of
AIDS patients with ESRD maintained on CAPD is not substan-
tially worse than survival of AIDS patients without ESRD
reported in the literature. Direct comparison of survival rates in
HIV infected patients with ESRD maintained on hemodialysis
versus CAPD cannot be made from available information. HIV
infected patients on CAPD have higher rates of peritonitis than
non-HIV infected patients on CAPD, but peritonitis related
complications rarely require discontinuation of CAPD. HIV
infected patients on CAPD should be trained on the Y-set, since
this was associated with lower rates of peritonitis. CAPD
deserves consideration as a therapy for HIV infected patients
with ESRD.
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